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Abstract: Extended bone fractures or fractures coexisting with bone disorders can lead to non-unions
where surgical intervention is required. Composite drug delivery systems are being used increasingly
more in order to treat such defects locally. Alendronate (ALD), a bisphosphonate extensively used
in clinical practice to treat conditions, such as osteoporosis, has been shown to assist bone fracture
healing through its antiresorptive capacity. This study reports the development of a polymeric
composite system for the in situ delivery of ALD, which possesses enhanced encapsulation efficiency
(EE%) and demonstrates controlled release over a 70-day period. ALD and calcium phosphate
(CaP) were incorporated within poly (lactic-co-glycolic acid) (PLGA) microspheres, giving rise to a
70% increase in EE% compared to a control system. Finally, a preliminary toxicological evaluation
demonstrated a positive effect of the system on pre-osteoblastic cells over 72 h.
Keywords: bone; bisphosphonate; biodegradable; drug delivery; controlled release; composite
1. Introduction
Bone performs a variety of tasks critical to human physiology [1]. Apart from its most commonly
acknowledged role as the body’s structural component, bone tissue also performs other functions, such
as the protection and support of other internal organs, production of blood cells, and storage of mineral
salts [2]. Bone tissue possesses some unique properties, such as self-remodeling and regeneration via
structural and formational tissue restoration [3–6]. In complex cases, damaged or diseased tissue is
unable to regenerate, and, in such cases, surgical intervention is required.
In the past, non-healing fractures were addressed surgically using rigid fixation devices, which
lack biodegradability but also restrict healing [7]. Research then shifted to the development of bone
grafts, namely autografts or allografts [1,2,5]. However, both types of graft are associated with limited
availability, prolonged recovery, donor-site morbidity, and disease transmittance. There is a clinical
need to develop a synthetic alternative [8,9].
Tissue engineering is a multidisciplinary field based on materials science and molecular biology [10].
The field focuses on the development of biological substitutes to replace damaged or diseased tissue or
to assist new tissue formation [11]. Within bone tissue engineering, such devices focus on the activation
of natural repair mechanisms [5,12]. A vast range of materials have been studied for the formulation
of such devices [2,5,7,13], including natural or synthetic polymers and ceramics, either individually or
in combination with bioactive compounds (growth factors, proteins, etc.) and/or cellular components
(mesenchymal stem cells). Research has shown that amongst the most successful are composite-based
devices, which incorporate hydrophilic polymers and inorganic mineral like hydroxyapatite (HA).
It is suggested that the incorporation of drugs, such as bisphosphonates (BPs), could further increase
the integration of devices within the host environment and subsequently reduce surgical recovery
times [6,14].
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Alendronate (ALD) is a type of BP and is clinically used to treat bone disorders, such as
osteoporosis [15,16]. Recently, it has been suggested that the introduction of ALD in osteoporotic
bone fractures could improve fracture healing [17]. Alendronate has been found to bind and thus
block “ . . . an enzyme in the 3-hydroxy-2-methylglutaryl-CoA (HMG-CoA) reductase pathway
(i.e., the mevalonate pathway), thus blocking the prenylation of small GTPases . . . ” as described by
Kyllönen [17]. GTPases are hydrolytic enzymes controlling the conversion of guanosine triphosphate
(GTP) to guanosine diphosphate (GDP) [18,19]. Ultimately, this has a detrimental effect on the function
and viability of osteoclasts, leading to a net increase in tissue.
Poly (lactic-co-glycolic acid) (PLGA) is a synthetic copolymer of polylactic acid (PLA) and
polyglycolic acid (PGA), which has been adopted in the production of various therapeutic devices,
including tissue grafts, surgical sutures, bone tissue engineering scaffolds, and drug carrier systems,
due to its excellent biocompatibility and ability to tune degradation [1,5]; the degradation rate can be
tailored based on the ratio of lactic to glycolic acid. Both PLA and PGA degrade via non enzymatic
hydrolysis, which is characterized by auto-catalysis due to the acidic nature of the degradation products
(carboxylic acids), and this constitutes a common feature amongst a-polyesters [20]. Co-polymerization
of lactic and glycolic acids is used to improve the degradation pattern. Their copolymers, PLGA
polymers, offer the possibility of controlling the degradation rate of the product by adjusting the glycolic
to lactic acid ratio, consequently controlling the release profile of bioactive molecules transported
in relevant carriers [21]. Degradation progresses through bulk erosion of ester bonds and it is also
affected by the architecture of the devices as well as the entrapped moieties. Unfortunately, the absence
of a linear correlation between the copolymer’s composition and its degradation profile has been
shown; for example, when the ratio is 50% PLGA, the system degrades faster than both PLA and PGA.
PLGA is U.S. Food and Drug Administration approved for use in humans and has been prepared
into several different formulations, including scaffolds, hydrogels, nanoparticles, microparticles, and
sponges. Consequently, PLGA is an attractive choice for bone regeneration [5].
Researchers have attempted to deliver ALD to local sites; however, achieving controlled release
can be challenging due to the high solubility of the drug. In this study, we aimed to create a composite
system for the local delivery of ALD to fracture sites via controlled release. This was achieved through
the development of PLGA and calcium phosphate (CaP) microparticles, which were loaded with the
active drug. CaP was selected in order to prolong the release of ALD, which is currently challenging,
through the formation of a mineral shell, which is hypothesized to decrease the degradation rate of
the system. This system would allow for the delivery of a drug to fracture sites, thus leading to a net
increase in bone formation. Although out of the scope of the current study, the composite system could
be incorporated within a hydrogel system to form an injectable material that could be delivered to the
site of injury.
2. Materials and Methods
2.1. Materials
Alendronate sodium salt (purity ≥ 95%) was purchased from Cayman Chemical (Ann Arbor, MI,
USA). Poly (lactic-co-glycolic acid) 50% was purchased from Lakeshore Biomaterials (Birmingham, AL,
USA). Dichloromethane (DCM) was purchased from Fisher Chemicals (Hampton, NH, USA). Nitric acid
(HNO3) and poly (vinyl alcohol) (PVA) (molecular weight 31,000–50,000, 98–99% hydrolyzed) were
purchased from Acros Organics (Fair Lawn, NJ, USA). All other chemicals and reagents were purchased
from Sigma-Aldrich (Gillingham, UK).
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2.2. Methods
2.2.1. CaP Particle Formation
CaP particles were prepared following a wet precipitation method as described by
Mobasherpour [22]. Briefly, a 0.29 M aqueous solution of (NH4)2HPO4 was added dropwise to
0.24 M aqueous solution of Ca(NO3)2.4H2O at a volume ratio of 1.4 Ca(NO3)2.4H2O to (NH4)2HPO4.
Synthesis was performed under stirring under atmospheric conditions. Mixing was performed using a
homogenizer (IKA® T25 digital, ULTRA TURRAX, Berlin, Germany) and the solution was maintained
at pH 10. The precipitate was washed with distilled water and collected by centrifugation at 3000 rpm
in 15-min cycles. Homogenization was performed at different speeds and durations and the size
distribution was examined at various time points under atmospheric conditions.
Physicochemical Characterization
The size distribution of the CaP particles was performed using a Malvern Mastersizer 2000
(Malvern Panalytical Ltd., Malvern, UK) via light scattering and the surface charge was evaluated
using a Malvern Zeta-sizer (Nano-ZS) using the Smoluchowski model. Prior to measurement, samples
underwent sonication for one hour to break down aggregates.
The chemical composition of the CaP particles was determined via Fourier transform infrared
spectroscopy (FT-IR) and X-ray fluorescence (XRF). For FT-IR analysis, sample pellets were formed into
mechanical mixtures of 1% mineral particle powder in potassium bromide (KBr). CaP particles were
thoroughly dried before analysis. For XRF analysis (50 kV, 300 µA, 25 µm spot size, 20 mbar vacuum),
samples were dried and pressed into pellets.
2.2.2. ALD-Loaded Microspheres
The microspheres (Msps) were prepared using a water-in-oil-in-water (w/o/w) double
emulsion-solvent evaporation method [23]. Briefly, 2.25 mL of PLGA 50% solution 2% w/v in
dichloromethane (DCM) were emulsified with 0.45 mL of 10% w/v PVA aqueous solution. For the
preparation of ALD-loaded microspheres, ALD was initially dissolved in the inner aqueous phase.
For the preparation of CaP-ALD-loaded particles, ALD was mixed with CaP particles’ aqueous
dispersion and allowed to bind for 24 h, and then mixed with 10% w/v PVA solution. The emulsification
was accomplished using a homogenizer (IKA® T25 digital, ULTRA TURRAX) at 8000 rpm for 30 s.
The primary emulsion was further emulsified using a magnetic stirrer with 42.2 mL of 10% w/v PVA
aqueous solution for 4 h until the organic phase fully evaporated. Microspheres were washed with
water to remove residual PVA and non-encapsulated drug, and collected using centrifugation (JOUAN
C422 centrifuge, Thermo Fisher Scientific) at 4000 rpm using 30-min cycles. The process was repeated
until the supernatant was clear and transparent. Finally, the microspheres were dried under vacuum
at room temperature for 24–48 h (Edwards High Vacuum, V&IP, Sussex, UK).
Microspheres’ Physicochemical Characterization and Drug Encapsulation
Spectrophotometric evaluation (CE 7500 Double Beam UV/Visible Spectrophotometer) of the
polymeric microspheres was carried out to calculate the ALD content. The method used was based on
the formation of an ALD-Cu(II) chromophoric complex absorbing at 240 nm according to the work
described by Ostovic [24–26].
Drug encapsulation in solid microspheres: 2 mg of particles were dispersed in 0.5 mL of DCM.
Then, 2 mL of nitric acid (HNO3) 1.5 mM were added and the mixture was stirred at 160 rpm for 20 min.
The aqueous phase was filtered, and 1 mL was diluted with 1 mL of 1.5 mM HNO3 and 2 mL of Cu+2
5 mM solution in 1.5 mM HNO3. The mixture was vortexed for 30 s and left in the dark for 20 min.
The sample’s absorbance was measured at 240 nm and used for calculating the ALD concentration.
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Size Distribution and Morphology
The size distribution of the fabricated microspheres was determined using optical microscopy
(ZEISS optical microscope) and a particle sizer (Malvern Mastersizer 2000). Particle morphology was
further evaluated using scanning electron microscopy (SEM) (JEOL JSM-6060LV). For SEM, samples
were dried and mounted on aluminum stubs and then subjected to platinum sputtering. Micrographs
were further examined using an image processing software (ImageJ). Density was examined using a
helium pycnometer (AccuPyc II 1340).
In Vitro Release
Particle dispersions in high-performance liquid chromatography (HPLC)-grade distilled water
were prepared at a concentration of 1 mg/mL and kept at 37 ◦C under 100 rpm shaking using a
temperature-controlled shaker. Dispersions were centrifuged at 4000 rpm for 30 min and 1 mL of
supernatant was drawn and used to measure the ALD concentration. Spectrophotometric evaluation
(CE 7500 Double Beam UV/Visible Spectrophotometer) of the polymeric microspheres was used to
calculate the ALD content. The method was based on the formation of an ALD-Cu(II) chromophoric
complex absorbing at 240 nm. In solution, alendronate bonds copper ions via chelate bonding.
Each alendronate molecule binds to one copper ion, leading to the formation of a chromophore that
absorbs photons at the ultraviolet spectrum. This property is exploited for the quantification analysis
of alendronate. To account for small amounts of remaining contaminants in the distilled water used,
negative control samples were used during the analysis containing empty micro particulate structures
of the same composition prepared following the same formulation process without alendronate.
These samples were used to form the baseline of the analysis.
Biocompatibility Evaluation
Preliminary toxicity experiments were conducted in order to assess the biocompatibility.
MC-3T3 cells (ATCC, Teddington, UK) were cultured in culture media; 84.6% v/v Alpha
Modified Minimum Essential Medium Eagle (A-MEM), 10% v/v fetal bovine serum (FBS), 2% v/v
L-glutamine (200 mM), 2.4% v/v 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (1 M), and 1% v/v
penicillin/streptomycin solution. Cells were initially grown in polystyrene tissue culture flasks and then
transferred to 96-well plates at a concentration of 4 × 104 cells per well to be treated with the polymeric
particles. Cells were cultured at 37 ◦C under 5% CO2 atmosphere and all procedures were conducted
under aseptic conditions. Particles were sterilized by overnight exposure to ultraviolet radiation.
Metabolic activity evaluation: The impact of the particles on metabolic activity was assessed using
the alamarBlue® assay. Briefly, reagent solution was added to the culture at 10% v/v and plates were
incubated at 37 ◦C for 4 h. The fluorescence was measured at an excitation of 540 nm and emission of
620 nm. The results were expressed as a percentage of the value corresponding to untreated cells.
2.2.3. Statistical Analysis
The Thompson Tau analysis was used to determine outliers and the average value and standard
deviation of the multiple replicates. Two-tailed unpaired Student’s T-test was performed to establish
statistically significant differences; here, p ≤ 0.05 are denoted by * and p ≤ 0.01 are denoted by **.
3. Results
3.1. CaP Particles
CaP particles were prepared under different conditions of mixing. The impact of aging on
the physical characteristics of the particles was examined. The effects of different homogenization
parameters (speed and duration) on the particle size distribution are presented in Table 1.
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Table 1. Influence of different homogenization parameters on the Ca/P particle size distribution during





Speed (rpm) Duration (min) SWA Median Diameter (d50)
1 7000 10
- 12.4 +/− 2.274 13.8 +/− 2.354
48 5.1 +/− 0.349 8.9 +/− 5.322
2 7000 30
- 7 +/− 1.948 9.1 +/− 3.398
48 6.0 +/− 0.093 7.9 +/− 0.066
3 10,000 30
- 2.8 +/− 0.163 3.1 +/− 0.210
48 2.6 +/− 0.009 2.8 +/− 0.006
4 10,000 60
- 2.9 +/− 0.239 3.2 +/− 0.407
48 2.4 +/− 0.332 2.6 +/− 0.057
Under 7000 rpm homogenization speed, an increase in homogenization time leads to a decrease
in the surface-weighted average (SWA) and d50 of the particle distribution. Longer homogenization
times led to a 56% reduction in the SWA diameter of the population. Aging the samples under low
stirring under bench conditions leads to a decrease in size at an average of 5.5 µm, regardless of the
initial mixing duration. When particles were prepared by mixing at 10,000 rpm, the size distribution
remained stable (SWA = 2.7 µm), regardless of the mixing or aging duration.
The size distribution of samples 3 and 4 were stable for 48 h, and their stability was further
examined as presented in Figure 1. Sample 3 parameters were chosen for the continuation of the study.
Particle density was evaluated using a helium pycnometer as presented in Table 2.
Figure 1. Ca/P particles’ size stability over time under bench conditions. Although statistically
significant, the size changes observed due to aging were not significant in magnitude, with the
maximum difference observed being 0.6 µm.
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PLGA microspheres 1.51 0.13
CaP-loaded PLGA microspheres 1.53 0.01
10% ALD-loaded PLGA microspheres 1.48 0.02
10% ALD-CaP-loaded PLGA microspheres 1.99 0.06
To investigate the identity of the formulated CaP particles, chemical analysis was performed via
FT-IR (Figure 2).
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Figure 2. FT-IR spectra of the as-prepared CaP particles prepared following the Mobasherpour protocol.
The data underwent baseline correction.
By comparing these spectra with the literature, we can identify peaks corresponding to OH-
stretching vibration from 3600–2600 cm−1, particularly close to 3570 cm−1 [10,27–30], and peaks
corresponding to P-OH around 1500 cm−1. The wide peak after 3000 cm−1 could suggest residual
moisture during the analysis as similar peaks appear during dissolution of calcium phosphate [31].
Dry CaP powder was examined by XRD (2θ = 5◦–60◦ at a rate 4◦/min using a Cu anode. Although the
signal to noise ratio from the acquired diffraction patterns was quite low, two major peaks were
observed, around 26◦ and 31◦ [10,29]. The same samples were also analyzed using XRF to further
investigate the phase of calcium phosphate present (Figure 3).
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3.2.1. Physical Characteristics
The encapsulation of ALD, CaP, or their conjugate does not affect the size distribution of the
polymeric particles as observed in Figure 4. Encapsulation of ALD appears to have a significant effect
on the morphology of the particles; samples of PLGA microspheres demonstrate a small number of
porous damaged structures, whilst ALD-loaded microspheres appear to be comprised mostly of highly
porous spheres and the incidence of damaged particles increased significantly. The incorporation of
ALD in the form of a mineral composite is not accompanied by the same porous structures. In Figure 4d,
the structures observed are predominantly spherical with a smooth surface similar to those in Figure 4b.
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Figure 4. Scanning electron microscopy was used to examine the morphology of particles (a) CaP
particles, (b) poly(lactic-co-glycolic acid) particles (10.525 µm), (c) ALD-loaded polymeric particles
(10.6 µm), and (d) ALD-CaP-loaded PLGA particles (9.13 µm). Scale bar 50 µm.
s porous structures ere observed, the density of different compositions was examined using a
helium pycnometer. The true density (g/cm3) of the samples is presented in Table 2.
The addition of CaP particles within the PLGA polymeric spheres does not have a significant effect
on the density of the structures. The encapsulation of ALD decreases the density and thus increases
the porosity of the spheres, which is in accordance with the morphological evaluation of their surface
(Figure 4c). The encapsulation of ALD in the form of an ALD-CaP conjugate leads to an increase in
density. It was also observed that the density of the ALD-CaP–PLG composites was higher than that
of PLGA or CaP-loaded PLGA microspheres.
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3.2.2. Encapsulation Efficiency (EE%)
ALD is highly hydrophilic and consequently not readily retained by polymeric structures, such as
PLGA microspheres. As observed in Figure 5, the entrapment efficiency of ALD by polymeric spheres
is low regardless of the initial loading. When the initial loading was 10% ALD and 10% ALD CaP, EE%
was 8% and 14%, respectively. Then, 20% ALD and 20% ALD CaP gave rise to 11.5% and 20.5% EE%.
An increase in loading from 10% to 20% did not have a significant effect on the EE%. Although there
is large deviation between samples, the incorporation of ALD in the form of a CaP conjugate leads
to a statistically significant increase in the EE%, which is further enhanced when combined with the
increase of the initial loading from 10% to 20%.J. Funct. Bi mater. 2020, 11, x FOR PEER REVIEW 9 of 14 
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Figure 5. The effect of CaP addition on the encapsulation efficiency (EE%) of ALD within PLGA
microspheres under different initial ALD loadings (10% and 20% w/w of PLGA). Six replicates were
performed for each composition (** p ≤ 0.01).
3.2.3. In Vitro Release
It is important to note that release studies were performed in distilled water instead of a
phosphate-buffered saline (PBS), a common buffer solution used in release studies. This decision was
based on the fact that the method used for the quantitative analysis of ALD is based on the formation
of a chromophoric complex between ALD and copper ions. Cu(II) ions bind to PO4−3 ions present in
PBS, creating a low-solubility chromophoric compound that would interfere with the analysis [32,33].
In the case of CaP-containing structures, this issue is overcome by the fact that the same mass of CaP
particles is used for the formation of ALD-loaded samples and empty samples used as blank, thus the
effect of the presence of PO4−3 is subtracted from the final concentration calculations.
Figure 6 demonstrates that 50% of ALD is released within the first 10 days from ALD-loaded
PLGA microspheres. However, there is little to no burst release from the ALD-CaP-loaded PLGA
microspheres. A short burst release was observed in the following five days and the cumulative release
remains stable for 50 days. The majority of ALD is released within three months. Statistical analysis
showed that there is a statistically significant difference in the release from the two compositions after
10 days and after 2 months.
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Figure 6. Cumulative release of ALD from PLGA microspheres in vitro. Particles’ suspension was set
at a concentration of 1 mg/mL in HPLC-grade distilled water, 37 ◦C, and suspensions were shaken at a
speed of 100 rpm. The final loading of ALD was 14 ug/mL (+/− 1.73) for ALD-loaded PLGA particles
and 20.67 µg/mL (+/− 2.08) for ALD-CaP-loaded PLGA particles (* p ≤ 0.05 and ** p ≤ 0.01).
3.2.4. Cytotoxicity Evaluation
Preliminary toxicological evaluation showed that the introduction of PLGA particles has no
negative impact on cellular viability, but on the contrary, there appears to be a positive effect. The values
corresponding to treated cells are close or higher than 100% in most cases. Although the increase in the
number of particles added per well initially leads to a decrease in cell viability %, after 72 h, the increase
of the particulate concentration consistently leads to a statistically significant increase in viability.
Other studies have shown that, although PLGA is generally inert, pre-osteoblasts have not only
shown good viability when cultured on PLGA scaffolds but also have exhibited bone-related protein
expression and fibril extracellular matrix formation [28]. Protein expression is enhanced by the presence
of HA due to its osteoinductive properties. It has also been suggested that the impact of HA could
be caused by the roughness of the mineral and increase in the hydrophilicity of systems based on
hydrophobic polymers like PLGA. Additionally, a previous co-culture of chondrocytes and osteoblasts
in the presence of PLGA and PLGA-bioglass microspheres has shown collagen deposition within the
first 10 days with no significant statistical differences between the two systems, proving the positive
effect of PLGA on the growth and functionality of bone cells [34]. The viability % increase over 100%
in comparison to untreated cells could be an effect of the physical presence of particles increasing
the surface area available for cell growth. According to Fu et al., the provision of a biocompatible
environment in the vicinity of small cellular clusters can lead to aggregation of the cells in that area
and an increase in the proliferation rate [28]. As alamarBlue is a metabolic activity assay, it is limited
by the fact that it does not differentiate between an increase in the number of cells or an increase in
metabolic activity, which could suggest that the increased signal over the first few days of culture
could be because of an increase the in cell number and not due to a change of the metabolic activity.
Preliminary toxicological evaluation showed that the introduction of particles has no negative impact
on cell viability of pre-osteoblasts.
4. Discussion
4.1. CaP Particles
In previous studies, it has been demonstrated that CaP particle preparation parameters not only
affect the size and morphology of the particles but also the phase of the mineral ranging from amorphous
hydroxyl apatite to brushite and finally to highly crystalline HA [22]. Specifically, high-temperature
post-formulation treatment leads to an increase in crystallinity and particle size. In order to obtain
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a significant loading of CaP particles in PLGA microspheres, the size difference between the two
structures needs to be maximized. For our formulations, we examined several preparation parameters
(mixing speed, mixing duration, and aging duration) in order to obtain the minimum average particle
diameter and obtain a narrow size distribution. For these reasons, the preparation was conducted at
room temperature and post-formulation heat treatment was avoided to minimize crystal growth.
It was concluded that the size distribution of the particles is affected by preparation parameters;
predominately, lower mixing speeds and aging leads to a decrease in size. As agglomerates have
been shown to form through cold welding from very fine particles, it was not something that could
be easily avoided. In order to decrease the effect that agglomerates have on further usage of the
particles, formulations were sonicated prior to utilization and characterization. Although preliminary
chemical analysis of those particles was performed using FTIR and XRF analysis, further analysis is
required to fully identify the calcium phosphate phases present in these particles. Our study also
focused on decreasing the size and crystallinity since highly crystalline HA particles appear to have
lower solubility [35], which would hinder the release of the ALD from the CaP particles after they are
released from the PLGA microspheres.
The size, morphology, and phase of CaP particles have also been linked to an inflammatory
response [36,37]. It has recently been shown that different shapes and sizes of HA particles can
influence the recruitment and response of immune cells and signaling molecules. Specifically, smaller
particles, less than 10 µm, have been associated with immunological responses; larger particles are
less toxic to the surrounding tissue post-injection. The particles formulated in this study were in
that range, predominantly to increase incorporation in the PLGA microspheres so this could be an
issue in in vivo administration as it can hinder bone remodeling, so it needs to be examined further.
Additionally, Lebre’s [37] study also showed that although needle-like fairly sharp particles can have
a negative effect on the cell structure as they can damage the cellular membrane, whereas smooth
spherical particles do not have the same effect. The particles reported in this research are spherical and
therefore should avoid such an immune response.
The incorporation of ALD into PLGA microspheres in the form of CaP conjugates could provide a
secondary release mechanism as such particles are soluble in low pH, which makes it an ideal vector for
delivering osteoclasts targeting ALD. The local pH in the lacuna created between osteoclast cells and
the bone surface is in the range of 4–5 due to the acidic excretions of osteoclasts [35]. Therefore, after the
release of CaP particles from PLGA microspheres packed into the fracture site, CaP particles are free to
bind to the existing bone surface due to the high affinity of these minerals to bone mineral. The proposed
mechanism is as CaP particles dissolve in the lacuna, ALD is gradually released. Once ALD is released
into the lacuna, endocytosis is facilitated by the high permeability of the osteoclast’s ruffled membrane.
Post-endocytosis, ALD hinders osteoclast activity and consequently the release of ALD from the
particles is based on a “feedback” mechanism.
4.2. ALD-Loaded PLGA Microspheres
The chemical composition of the particles significantly affects their physical structure.
All compositions led to spherical structures of a similar size distribution, but the surface morphology
and the bulk density of the spheres varied. Surface morphology, roughness, and density can all
influence the response of a drug delivery system with the host tissue and can also play an important
role in the delivery mechanism of the entrapped drug. The incorporation of ALD in the form of a CaP
conjugate led to a statistically significant improvement in the encapsulation efficiency (70% increase)
of ALD. This is explained by the fact that ALD as a bisphosphonate exhibits a high affinity to bone
mineral like HA [38,39]. Additionally, the formulation of less porous structures leads to a decrease
in the loss of ALD during fabrication due to diffusion from the inner to the outer aqueous phase.
The highly porous structure of ALD-loaded particles explains the initial burst release observed in the
first 10 days of the release studies of this system as well as in similar systems [15]. On the contrary, the
addition of ALD as a conjugate with CaP particles leads to a significant decrease in porosity, which is
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used as a way to decrease ALD release via diffusion through the polymeric structure. Most importantly,
the study showed that this composite system provides a controlled and prolonged release of ALD
that could assist bone healing over a period of 70 days. Finally, preliminary toxicological experiments
displayed no significant negative impact on the growth of MC-3T3 cells, a pre-osteoblastic cell line,
in the presence of such a structure. The impact of the PLGA degradation in in vitro conditions was
tested via the preliminary experiment described in this study (Figure 7). Although, the treated cultures
exhibited improved signs of cellular health in comparison to untreated cells and the literature supports
the use of these materials for in vivo applications, the authors acknowledge the need for extended
experimental studies to evaluate the impact of the developed CaP-PLGA composite structure in cellular
and tissue environments to investigate any potential inflammatory-inducing effects before the system
can progress to animal studies. Preliminary data suggests that the presence of these structures could
promote the growth of these cells, which is explained by the osteoconductive capacity of these materials.
The above work supports the safety of these structures in cellular environments.J. Funct. Biomater. 2020, 11, x FOR PEER REVIEW 12 of 14 
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5. Conclusions
This study aimed to develop a composite drug delivery system, which has the ability to deliver
ALD to fracture sites in a controlled manner. The system, composed of PLGA ALD-CaP, demonstrated
controlled release over 70 days, with increased encapsulation efficiency upon the addition of CaP.
Future work will look at developing an injectable carrier system that will allow the delivery of
particles to the sites of injury. Extensive studies to determine osteoblast and osteoclast activity, as
well as investigating the in vivo effects of the particles on the healing of critical-sized defects, will also
be conducted.
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